Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryota Hashimoto

Showing results (391-400 of 467) with videos related to

Pageof 47
Sort By:
The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|November 29, 2022
Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" projectHitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, et al.
Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|June 6, 2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site studyHiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Nature Communications|February 28, 2020
Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypesKensuke Matsumura, Kaoru Seiriki, Shota Okada, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|October 10, 2022
Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysisTakashi Tsuboi, Yoshikazu Takaesu, Naomi Hasegawa, et al.
Molecular Psychiatry|November 30, 2019
White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individualsDaisuke Koshiyama, Masaki Fukunaga, Naohiro Okada, et al.
Psychiatry and Clinical Neurosciences|March 11, 2026
Psychometrics of BE-PSD-V2.0 and its correspondence with PANSS and CGI-SHiroyoshi Takeuchi, Naoki Hashimoto, Yoshiteru Takekita, et al.
Pageof 47

Showing results (391-400 of 467) with videos related to

Sort By:
Pageof 47
The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|November 29, 2022
Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" projectHitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, et al.
Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|June 6, 2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site studyHiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Nature Communications|February 28, 2020
Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypesKensuke Matsumura, Kaoru Seiriki, Shota Okada, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|October 10, 2022
Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysisTakashi Tsuboi, Yoshikazu Takaesu, Naomi Hasegawa, et al.
Molecular Psychiatry|November 30, 2019
White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individualsDaisuke Koshiyama, Masaki Fukunaga, Naohiro Okada, et al.
Psychiatry and Clinical Neurosciences|March 11, 2026
Psychometrics of BE-PSD-V2.0 and its correspondence with PANSS and CGI-SHiroyoshi Takeuchi, Naoki Hashimoto, Yoshiteru Takekita, et al.
Pageof 47